Skip to content
← All settings

DISEASE & TREATMENT SETTING

metastatic Skin Cancer

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Metastatic Basal Cell Carcinoma (or Locally Advanced Disease Untreatable by Local Modalities)

Broader topic: Skin Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
      source wording
      Treatment of Metastatic Basal Cell Carcinoma (or Locally Advanced Disease Untreatable by Local Modalities)

      Study evidence for this setting

      11 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT01274338 · Source cited / selected · Scope: unclear

      Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

      6 outcome links · 6 safety-group records · 3 quality-of-life measures

      →

      NCT02123511 · Registry condition search · Scope: unclear

      Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

      6 outcome links · 2 safety-group records · 3 quality-of-life measures

      →

      NCT02180867 · Source cited / selected · Scope: unclear

      Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can

      6 outcome links · 7 safety-group records · 2 quality-of-life measures

      →

      NCT02224781 · Source cited / selected · Scope: unclear

      Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Mel

      6 outcome links · 4 safety-group records · 0 quality-of-life measures

      →

      NCT02595866 · Registry condition search · Scope: unclear

      Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

      6 outcome links · 5 safety-group records · 0 quality-of-life measures

      →

      NCT02650986 · Registry condition search · Scope: unclear

      Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

      5 outcome links · 4 safety-group records · 0 quality-of-life measures

      →

      NCT02721732 · Registry condition search · Scope: unclear

      Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03108131 · Registry condition search · Scope: unclear

      Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

      4 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT03154190 · Registry condition search · Scope: unclear

      Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

      6 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT03698019 · Source cited / selected · Scope: unclear

      A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

      5 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT04514484 · Registry condition search · Scope: unclear

      Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice